Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Otenzepad SCHEMBL24305002 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| Otenzepad SCHEMBL29363384 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| Otenzepad SCHEMBL29482389 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL10508725 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL10508758 | 0.97 | CYP1A2 (0.95) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL10930746 | 0.97 | CYP1A2 (0.95) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL10927709 | 0.93 | CYP1A2 (0.86) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL10510299 | 0.92 | CYP1A2 (0.85) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL10509915 | 0.92 | CYP1A2 (0.85) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL9597030 | 0.92 | CYP1A2 (0.85) | CYP1A2CYP3A4CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372357-A1 | STABLE PHARMACEUTICAL COMPOSITION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-23 | — | — | US | claimed |
| WO-2023190663-A1 | HIGH-PURITY COMPOUND PRODUCTION METHOD AND PURIFICATION METHOD | 参天製薬株式会社 | 2023-10-05 | — | — | WO | claimed |
| EP-4230210-A1 | STABLE PHARMACEUTICAL COMPOSITION | Santen Pharmaceutical Co., Ltd. (JP) | 2023-08-23 | — | — | EP | claimed |
| US-20230190766-A1 | AGENT FOR TREATING MYOPIA, PREVENTING MYOPIA AND/OR SUPPRESSING MYOPIA PROGRESSION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | claimed |
| EP-4192471-A1 | AGENT FOR TREATING MYOPIA, PREVENTING MYOPIA AND/OR SUPPRESSING MYOPIA PROGRESSION | Santen Pharmaceutical Co., Ltd. (JP) | 2023-06-14 | — | — | EP | claimed |
| EP-1148880-B1 | METHODS FOR RESTORING AND/OR ENHANCING ACCOMMODATION IN PSEUDO PHAKIA | ADVANCED MEDICAL OPTICS INC (US) | 2006-12-13 | — | — | EP | claimed |
| US-20050251254-A1 | Method of implanting accommodating intraocular lenses | ADVANCED MEDICAL OPTICS, INC. | 2005-11-10 | — | — | US | claimed |
| EP-1100480-B1 | MUSCARINIC ANTAGONISTS IN THE TREATMENT OF PRESBYOPIA | ALLERGAN INC (US) | 2003-09-24 | — | — | EP | claimed |
| US-6164282-A | Methods for restoring and/or enhancing accommodation in pseudo phakia | ALLERGAN SALES, INC. (US) | 2000-12-26 | — | — | US | claimed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | claimed |
| US-20250213588-A1 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-07-03 | — | — | US | disclosed |
| US-20250214992-A1 | HIGH-PURITY COMPOUND PRODUCTION METHOD AND PURIFICATION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-07-03 | — | — | US | disclosed |
| EP-4506347-A1 | HIGH-PURITY COMPOUND PRODUCTION METHOD AND PURIFICATION METHOD | Santen Pharmaceutical Co., Ltd. (JP) | 2025-02-12 | — | — | EP | disclosed |
| EP-4501329-A1 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | Santen Pharmaceutical Co., Ltd. (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-12156868-B2 | Formulations of pilocarpine and brimonidine compounds and related methods | SOMERSET THERAPEUTICS, LLC (US) | 2024-12-03 | — | — | US | disclosed |
| EP-0312895-A2 | Condensed diazepinones, process for their preparation and medicament containing them | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | disclosed |
| EP-0306698-A1 | Condensed diazepinones, processes for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0273239-A1 | Condensed diazepinones, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1988-07-06 | — | — | EP | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0156191-A2 | Condensed diazepinones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213588-A1 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | PIR, ZP1, CYP2C19 | CYP1A2 159/4885CYP3A4 203/4885CHRM2 1779/4885 |
| US-20230372357-A1 | STABLE PHARMACEUTICAL COMPOSITION | ADRA1B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADRA1A | CYP1A2 234/4885CYP3A4 189/4885CHRM2 298/4885 |
| US-12156868-B2 | Formulations of pilocarpine and brimonidine compounds and related methods | PDE6C, PDE6H, SLC6A11 | CYP1A2 959/4885CYP3A4 442/4885CHRM2 16/4885 |
| US-20250214992-A1 | HIGH-PURITY COMPOUND PRODUCTION METHOD AND PURIFICATION METHOD | GABRA6, CHRNA6, CHRNA5 | CYP1A2 192/4885CYP3A4 185/4885CHRM2 264/4885 |
| US-20230190766-A1 | AGENT FOR TREATING MYOPIA, PREVENTING MYOPIA AND/OR SUPPRESSING MYOPIA PROGRESSION | MTNR1B, MTNR1A, CHRNA1 | CYP1A2 2614/4885CYP3A4 3341/4885CHRM2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.